drugset / Trial / NCT04472572

Expanded Access to Convalescent Plasma for Treatment of COVID-19

NCT04472572

Expanded access No longer available Hackensack Meridian Health

Summary

This expanded access program will provide access to investigational convalescent plasma for patients at Hackensack University Medical Center infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.

Timeline

Start
Primary completion
Completion

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Convalescent Plasma Protein / enzyme biologic Other

Indications